PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Phentermine is a sympathomimetic amine that stimulates norepinephrine release in the hypothalamus, reducing appetite. Topiramate modulates GABA-A receptors, inhibits AMPA/kainate glutamate receptors, and inhibits carbonic anhydrase, enhancing satiety and reducing cravings.
| Metabolism | Phentermine is partially metabolized by CYP3A4 to N-hydroxyphentermine; topiramate is not extensively metabolized (~70% excreted unchanged), with minor metabolism via hydroxylation, hydrolysis, and glucuronidation. |
| Excretion | Phentermine: Renal (80% unchanged, 20% as metabolites). Topiramate: Renal (70% unchanged, 30% metabolized). Total dose eliminated renally: >90% combined. |
| Half-life | Phentermine: 20-25 hours (terminal); Topiramate: 19-23 hours (healthy adults), prolonged in renal impairment (up to 35 hours). Clinical context: Steady state reached in 4-5 days; supports once-daily dosing. |
| Protein binding | Phentermine: 50-60% bound (albumin). Topiramate: 15-41% bound (albumin). |
| Volume of Distribution | Phentermine: 3-4 L/kg (extensive tissue distribution including brain). Topiramate: 0.6-0.8 L/kg (predominantly extracellular fluid). |
| Bioavailability | Phentermine: 100% oral (immediate release). Topiramate: 80-100% oral (food not clinically significant). |
| Onset of Action | Oral: Weeks to months for weight loss; peak effect at 6-12 weeks. Immediate appetite suppression may occur within days but objective weight loss requires sustained therapy. |
| Duration of Action | Phentermine: Supports once-daily dosing (24-hour effect on satiety). Topiramate: Sustained release due to long half-life; clinical weight loss effect persists with continuous dosing; note: 24-hour duration for weight loss. |
Oral: Initial 3.75 mg phentermine / 23 mg topiramate once daily for 14 days, then increase to 7.5 mg/46 mg once daily. If <3% weight loss after 12 weeks, discontinue or escalate to 15 mg/92 mg once daily.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | CrCl ≥50 mL/min: No adjustment. CrCl 30-49 mL/min: Limit to 7.5 mg/46 mg once daily. CrCl <30 mL/min: Contraindicated. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Limit to 7.5 mg/46 mg once daily. Child-Pugh C: Contraindicated. |
| Pediatric use | Not approved for use in pediatric patients aged <18 years. No established dosing guidelines. |
| Geriatric use | No specific dose adjustment. However, use with caution due to age-related renal impairment; consider renal function and start at lowest dose. Not recommended in patients >65 years due to limited data. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Can decrease efficacy of oral contraceptives and other drugs by inducing CYP450 enzymes Can cause metabolic acidosis and angle-closure glaucoma.
| Breastfeeding | Excretion in human milk unknown. Both components may be present; topiramate achieves M/P ratio ~0.7-0.9. Avoid breastfeeding due to potential adverse effects in infant (e.g., diarrhea, somnolence). |
| Teratogenic Risk | Phentermine/topiramate is pregnancy category X. First trimester: Increased risk of oral clefts (topiramate). Second/third trimester: Potential for fetal growth restriction, oligohydramnios, and metabolic acidosis. Topiramate may cause neural tube defects if folate antagonist effects are not mitigated. |
■ FDA Black Box Warning
None.
| Common Effects | migraine prevention |
| Serious Effects |
["Pregnancy, glaucoma, hyperthyroidism, MAO inhibitor use within 14 days, hypersensitivity to sympathomimetic amines, agitated states, history of drug abuse, during or within 14 days of MAOI use."]
| Precautions | ["Increased heart rate, suicidal behavior/ideation, acute myopia/secondary angle closure glaucoma, mood disorders, cognitive impairment, metabolic acidosis, seizures (with topiramate withdrawal), pancreatitis, kidney stones, hypohidrosis/hyperthermia, fetal toxicity (orofacial clefts)."] |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth via ultrasound and amniotic fluid index. Assess for signs of oligohydramnios. In neonates, monitor for hypoglycemia, hyperbilirubinemia, and metabolic acidosis. Maternal monitoring includes renal function, electrolytes, and metabolic acidosis risk. |
| Fertility Effects | Topiramate may cause menstrual irregularities and anovulation. Phentermine may reduce fertility due to weight loss. Reversible upon discontinuation. |